| 1 | replacement products are lifesaving | | | | | | | 2 | 0.26% |
| 2 | for managed care and | | | | | | | 2 | 0.26% |
| 3 | latest expert interview latest | | | | | | | 2 | 0.26% |
| 4 | unfavorable in terms of | | | | | | | 2 | 0.26% |
| 5 | managed care and payer | | | | | | | 2 | 0.26% |
| 6 | factor replacement products are | | | | | | | 2 | 0.26% |
| 7 | with hemophilia are being | | | | | | | 1 | 0.13% |
| 8 | impact of copay accumulator | | | | | | | 1 | 0.13% |
| 9 | how do you perceive | | | | | | | 1 | 0.13% |
| 10 | do you perceive the | | | | | | | 1 | 0.13% |
| 11 | you perceive the impact | | | | | | | 1 | 0.13% |
| 12 | perceive the impact of | | | | | | | 1 | 0.13% |
| 13 | the impact of copay | | | | | | | 1 | 0.13% |
| 14 | andor maximization programs as | | | | | | | 1 | 0.13% |
| 15 | adjustment andor maximization programs | | | | | | | 1 | 0.13% |
| 16 | apply q3 how do | | | | | | | 1 | 0.13% |
| 17 | maximization programs as they | | | | | | | 1 | 0.13% |
| 18 | programs as they pertain | | | | | | | 1 | 0.13% |
| 19 | as they pertain to | | | | | | | 1 | 0.13% |
| 20 | they pertain to hemophilia | | | | | | | 1 | 0.13% |
| 21 | and other inherited bleeding | | | | | | | 1 | 0.13% |
| 22 | q3 how do you | | | | | | | 1 | 0.13% |
| 23 | not apply q3 how | | | | | | | 1 | 0.13% |
| 24 | hemophilia are being managed | | | | | | | 1 | 0.13% |
| 25 | 11 to 20 21 | | | | | | | 1 | 0.13% |
| 26 | are being managed in | | | | | | | 1 | 0.13% |
| 27 | your plan or practice | | | | | | | 1 | 0.13% |
| 28 | plan or practice setting? | | | | | | | 1 | 0.13% |
| 29 | 1 to 10 11 | | | | | | | 1 | 0.13% |
| 30 | to 10 11 to | | | | | | | 1 | 0.13% |
| 31 | 10 11 to 20 | | | | | | | 1 | 0.13% |
| 32 | to 20 21 to | | | | | | | 1 | 0.13% |
| 33 | does not apply q3 | | | | | | | 1 | 0.13% |
| 34 | 20 21 to 50 | | | | | | | 1 | 0.13% |
| 35 | 21 to 50 51 | | | | | | | 1 | 0.13% |
| 36 | to 50 51 to | | | | | | | 1 | 0.13% |
| 37 | 50 51 to 100 | | | | | | | 1 | 0.13% |
| 38 | patients with hemophilia are | | | | | | | 1 | 0.13% |
| 39 | many patients with hemophilia | | | | | | | 1 | 0.13% |
| 40 | 51 to 100 100 | | | | | | | 1 | 0.13% |